Fig. 6: MSCs enhanced cancer stem cell property of liver cancer cell in the Ps of hepatocarcinoma development.
From: The distinct roles of mesenchymal stem cells in the initial and progressive stage of hepatocarcinoma
a Immunostaining for EpCAM and CD133 in the rat liver of DEN and DEN + MSC (Ps) group. The positive staining was quantified by Image-Pro Plus software (right panel) (bar: 100 μm). b CBRH-7919 cells were treated by MSC-CM or MSC (IF)-CM for 48 h. And cell lysed to assess the expression of stem cell markers by immunoblot with indicated antibodies. c Clonogenic ability of CBRH-7919 cells upon the MSC or MSC (IF)-CM exposure was examined using clonogenic assay. A representative photograph is provided in the left panel, and quantified data are shown in the right panel. d Cell viability was measured using CCK8 assay. 7919 cells were treated with cisplatin with MSC-CM or MSC (IF)-CM exposure. Values are shown as mean ± SEM (*P < 0.05, **P < 0.01, ***P < 0.001). Representative of four independent experiments
